Innoviva (NASDAQ:INVA) Earns Overweight Rating from Analysts at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage on shares of Innoviva (NASDAQ:INVAFree Report) in a research note published on Tuesday morning, Marketbeat reports. The firm issued an overweight rating on the biotechnology company’s stock. Cantor Fitzgerald also issued estimates for Innoviva’s FY2024 earnings at $1.09 EPS.

Several other analysts have also recently weighed in on INVA. StockNews.com raised shares of Innoviva from a hold rating to a buy rating in a research note on Friday, March 29th. TheStreet upgraded shares of Innoviva from a c rating to a b- rating in a report on Thursday, February 29th.

View Our Latest Stock Analysis on Innoviva

Innoviva Stock Performance

NASDAQ:INVA opened at $15.90 on Tuesday. The company has a market cap of $992.80 million, a price-to-earnings ratio of 7.16 and a beta of 0.58. The firm’s 50-day moving average is $15.62 and its 200-day moving average is $15.61. Innoviva has a 52-week low of $12.22 and a 52-week high of $16.86. The company has a debt-to-equity ratio of 0.63, a quick ratio of 9.17 and a current ratio of 10.42.

Innoviva (NASDAQ:INVAGet Free Report) last posted its earnings results on Wednesday, May 8th. The biotechnology company reported $0.46 earnings per share for the quarter. The business had revenue of $77.50 million for the quarter. Innoviva had a net margin of 58.21% and a return on equity of 28.94%.

Institutional Investors Weigh In On Innoviva

Hedge funds have recently bought and sold shares of the company. Baader Bank Aktiengesellschaft acquired a new stake in Innoviva in the fourth quarter worth $257,000. Hillsdale Investment Management Inc. bought a new stake in shares of Innoviva during the fourth quarter worth $4,663,000. CWA Asset Management Group LLC bought a new stake in shares of Innoviva during the fourth quarter worth $4,070,000. PNC Financial Services Group Inc. increased its position in shares of Innoviva by 2.7% during the third quarter. PNC Financial Services Group Inc. now owns 46,109 shares of the biotechnology company’s stock worth $599,000 after acquiring an additional 1,234 shares in the last quarter. Finally, Gerber LLC bought a new position in Innoviva in the fourth quarter valued at $550,000. 99.12% of the stock is currently owned by institutional investors and hedge funds.

Innoviva Company Profile

(Get Free Report)

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

Read More

Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter.